Scarica l'app Stockscreener
22.08
0.36%
-0.11
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Hedge Fund Moves: Will Zenas BioPharma Inc benefit from geopolitical trends2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.5%Should You Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Wall Street Recap: What are Zenas BioPharma Inc.’s technical support levels - baoquankhu1.vn
ENAVATE Sciences Increases Zenas BioPharma Holding to 28% of PortfolioNews and Statistics - IndexBox
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch - The Motley Fool
Analyst Downgrade: Will Zenas BioPharma Inc outperform during market ralliesMarket Sentiment Summary & Growth Focused Investment Plans - baoquankhu1.vn
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Wedbush reiterates Zenas BioPharma (ZBIO) outperform recommendation - MSN
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis - TipRanks
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
HC Wainwright Forecasts Lower Earnings for Zenas BioPharma - MarketBeat
A Look At Zenas BioPharma (ZBIO) Valuation As Losses Widen And Going Concern Risks Emerge - Sahm
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Zenas BioPharma (ZBIO) Is Down 9.4% After Non-Dilutive Funding And Shelf Filing UpdateHas The Bull Case Changed? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Citigroup Issues Pessimistic Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
ZBIO: HC Wainwright & Co. Reiterates Buy Rating with $44 PT | ZB - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results - MarketBeat
Zenas BioPharma price target raised to $55 from $45 at Guggenheim - TipRanks
BioPharma Credit to Invest $125 Million in Zenas BioPharma - marketscreener.com
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares - Yahoo Finance
Biopharma Credit enters senior secured loan agreement with Zenas BioPharma for up to $125 mln - marketscreener.com
Biopharma Credit Enters Senior Secured Loan Agreement With Zenas Biopharma For Up To $125 Mln - TradingView
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma - TipRanks
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 - AlphaStreet
Zenas BioPharma (ZBIO) EPS Loss Narrows To US$2.05 Tests Growth Focused Bullish Narratives - simplywall.st
Zenas BioPharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Guggenheim raises Zenas Biopharma stock price target to $55 on pipeline progress - Investing.com Canada
New Zenas BioPharma hires receive 235,700 options, 33,450 RSUs - Stock Titan
Zenas BioPharma, Inc. ($ZBIO) Founder, CEO and COB 2025 Pay Revealed - Quiver Quantitative
Zenas BioPharma Reports 2025 Financial Results, Advances Obexelimab for IgG4-RD and SLE, Secures $250M Pharmakon Financing - Minichart
Morgan Stanley raises Zenas Biopharma stock price target on IgG4-RD outlook - Investing.com Canada
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.2%What's Next? - MarketBeat
Zenas BioPharma 2025 Annual Report: Advancing Obexelimab and I&I Therapies, Clinical Milestones, and Strategic Partnerships - Minichart
[ARS] Zenas BioPharma, Inc. SEC Filing - Stock Titan
Zenas BioPharma (NASDAQ: ZBIO) plans 2026 virtual meeting, director votes - Stock Titan
Zenas BioPharma 2025 10‑K: $10.0M revenue, GAAP loss $8.44/share - TradingView
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share - marketscreener.com
Obexelimab Phase 3 success anchors Zenas BioPharma (ZBIO) immunology pipeline - Stock Titan
Zenas reports $10.0M revenue, $377.7M net loss for FY2025; cash $360.5M - TradingView
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoYZenas BioPharma (NASDAQ:ZBIO) - Benzinga
Zenas BioPharma (Nasdaq: ZBIO) widens 2025 loss but lines up $250M Pharmakon financing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
ArrowMark Colorado Holdings LLC Reduces Stock Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings - Sahm
Tech Rally: Will Zenas BioPharma Inc benefit from geopolitical trendsJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Zenas Biopharma Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
ZBIO SEC FilingsZenas BioPharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 18.8% in February - MarketBeat
The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Obexelimab’s Commercial Pivot And Cash War Chest - simplywall.st
What is the target price for Zenas BioPharma Inc stockPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):